iData Insights

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 03, 2016 14:54 IST

This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179116/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179116/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Bile Duct Cancer (Cholangiocarcinoma) Overview 10

Therapeutics Development 11

Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 11

Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 12

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 13

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 18

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 22

Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 26

Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 27

4SC AG 27

Agios Pharmaceuticals, Inc. 28

Ariad Pharmaceuticals, Inc. 29

ArQule, Inc. 30

Array BioPharma Inc. 31

Arrien Pharmaceuticals, LLC 32

Aslan Pharmaceuticals Pte. Ltd. 33

Bayer AG 34

BIND Therapeutics, Inc. 35

Blueprint Medicines 36

Boehringer Ingelheim GmbH 37

Boston Biomedical, Inc. 38

Bristol-Myers Squibb Company 39

Celgene Corporation 40

CellAct Pharma GmbH 41

Cellceutix Corporation 42

Concordia Healthcare Corp. 43

Cornerstone Pharmaceuticals, Inc. 44

Delcath Systems, Inc. 45

Eisai Co., Ltd. 46

Eli Lilly and Company 47

Exelixis, Inc. 48

F. Hoffmann-La Roche Ltd. 49

Johnson & Johnson 50

Komipharm International Co., Ltd. 51

Loxo Oncology, Inc. 52

Mebiopharm Co., Ltd. 53

MedImmune, LLC 54

Merck & Co., Inc. 55

Merrimack Pharmaceuticals, Inc. 56

NanoCarrier Co., Ltd. 57

NormOxys, Inc. 58

Novartis AG 59

NuCana BioMed Limited 60

OncoTherapy Science, Inc. 61

Ono Pharmaceutical Co., Ltd. 62

Panacea Pharmaceuticals, Inc. 63

PCI Biotech AS 64

Pfizer Inc. 65

Plexxikon Inc. 66

Provecs Medical GmbH 67

Sanofi 68

Senhwa Biosciences, Inc. 69

Spectrum Pharmaceuticals, Inc. 70

Sun Pharma Advanced Research Company Ltd. 71

Threshold Pharmaceuticals, Inc. 72

VasGene Therapeutics, Inc. 73

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 74

Assessment by Monotherapy Products 74

Assessment by Combination Products 75

Assessment by Target 76

Assessment by Mechanism of Action 80

Assessment by Route of Administration 83

Assessment by Molecule Type 85

Drug Profiles 87

(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 87

afatinib dimaleate - Drug Profile 89

AG-120 - Drug Profile 94

ARN-5032 - Drug Profile 96

ARQ-087 - Drug Profile 97

BBI-503 - Drug Profile 98

binimetinib - Drug Profile 100

BLU-554 - Drug Profile 105

cabozantinib s-malate - Drug Profile 106

CAP-7.1 - Drug Profile 110

CC-90007 - Drug Profile 112

cisplatin - Drug Profile 115

CPI-613 - Drug Profile 117

dasatinib - Drug Profile 119

DKN-01 - Drug Profile 122

docetaxel - Drug Profile 124

durvalumab - Drug Profile 127

evofosfamide - Drug Profile 131

gemcitabine hydrochloride - Drug Profile 139

Im-01 - Drug Profile 140

IMB-101 - Drug Profile 141

IMB-102 - Drug Profile 142

infigratinib - Drug Profile 143

JNJ-42756493 - Drug Profile 144

KM-3174 - Drug Profile 146

KML-001 - Drug Profile 150

lenvatinib - Drug Profile 152

LOXO-101 - Drug Profile 158

MBPY-005 - Drug Profile 160

melphalan - Drug Profile 161

merestinib - Drug Profile 164

MK-2206 - Drug Profile 165

napabucasin - Drug Profile 168

nivolumab - Drug Profile 171

NUC-1031 - Drug Profile 178

OCVC-01 - Drug Profile 180

OXY-111A - Drug Profile 181

paclitaxel albumin bound - Drug Profile 183

paclitaxel albumin free - Drug Profile 187

PAN-622 - Drug Profile 189

pembrolizumab - Drug Profile 190

PLX-8394 - Drug Profile 199

ponatinib hydrochloride - Drug Profile 201

porfimer sodium - Drug Profile 204

refametinib - Drug Profile 206

regorafenib - Drug Profile 209

resminostat - Drug Profile 213

RRX-001 - Drug Profile 218

SAR-408701 - Drug Profile 220

seribantumab - Drug Profile 221

silmitasertib - Drug Profile 224

SPI-1620 - Drug Profile 226

sunitinib malate - Drug Profile 228

trametinib dimethyl sulfoxide - Drug Profile 232

Vaccine for Metastatic Cholangiocarcinoma - Drug Profile 235

varlitinib - Drug Profile 236

Vas-01 - Drug Profile 239

vemurafenib - Drug Profile 241

Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 245

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 387

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 389

Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 390

Featured News & Press Releases 390

Appendix 398

Methodology 398

Coverage 398

Secondary Research 398

Primary Research 398

Expert Panel Validation 398

Contact Us 398

Disclaimer 399" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Bile Duct Cancer (Cholangiocarcinoma) Overview 10

Therapeutics Development 11

Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 11

Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 12

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 13

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 18

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 22

Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 26

Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 27

4SC AG 27

Agios Pharmaceuticals, Inc. 28

Ariad Pharmaceuticals, Inc. 29

ArQule, Inc. 30

Array BioPharma Inc. 31

Arrien Pharmaceuticals, LLC 32

Aslan Pharmaceuticals Pte. Ltd. 33

Bayer AG 34

BIND Therapeutics, Inc. 35

Blueprint Medicines 36

Boehringer Ingelheim GmbH 37

Boston Biomedical, Inc. 38

Bristol-Myers Squibb Company 39

Celgene Corporation 40

CellAct Pharma GmbH 41

Cellceutix Corporation 42

Concordia Healthcare Corp. 43

Cornerstone Pharmaceuticals, Inc. 44

Delcath Systems, Inc. 45

Eisai Co., Ltd. 46

Eli Lilly and Company 47

Exelixis, Inc. 48

F. Hoffmann-La Roche Ltd. 49

Johnson & Johnson 50

Komipharm International Co., Ltd. 51

Loxo Oncology, Inc. 52

Mebiopharm Co., Ltd. 53

MedImmune, LLC 54

Merck & Co., Inc. 55

Merrimack Pharmaceuticals, Inc. 56

NanoCarrier Co., Ltd. 57

NormOxys, Inc. 58

Novartis AG 59

NuCana BioMed Limited 60

OncoTherapy Science, Inc. 61

Ono Pharmaceutical Co., Ltd. 62

Panacea Pharmaceuticals, Inc. 63

PCI Biotech AS 64

Pfizer Inc. 65

Plexxikon Inc. 66

Provecs Medical GmbH 67

Sanofi 68

Senhwa Biosciences, Inc. 69

Spectrum Pharmaceuticals, Inc. 70

Sun Pharma Advanced Research Company Ltd. 71

Threshold Pharmaceuticals, Inc. 72

VasGene Therapeutics, Inc. 73

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 74

Assessment by Monotherapy Products 74

Assessment by Combination Products 75

Assessment by Target 76

Assessment by Mechanism of Action 80

Assessment by Route of Administration 83

Assessment by Molecule Type 85

Drug Profiles 87

(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 87

afatinib dimaleate - Drug Profile 89

AG-120 - Drug Profile 94

ARN-5032 - Drug Profile 96

ARQ-087 - Drug Profile 97

BBI-503 - Drug Profile 98

binimetinib - Drug Profile 100

BLU-554 - Drug Profile 105

cabozantinib s-malate - Drug Profile 106

CAP-7.1 - Drug Profile 110

CC-90007 - Drug Profile 112

cisplatin - Drug Profile 115

CPI-613 - Drug Profile 117

dasatinib - Drug Profile 119

DKN-01 - Drug Profile 122

docetaxel - Drug Profile 124

durvalumab - Drug Profile 127

evofosfamide - Drug Profile 131

gemcitabine hydrochloride - Drug Profile 139

Im-01 - Drug Profile 140

IMB-101 - Drug Profile 141

IMB-102 - Drug Profile 142

infigratinib - Drug Profile 143

JNJ-42756493 - Drug Profile 144

KM-3174 - Drug Profile 146

KML-001 - Drug Profile 150

lenvatinib - Drug Profile 152

LOXO-101 - Drug Profile 158

MBPY-005 - Drug Profile 160

melphalan - Drug Profile 161

merestinib - Drug Profile 164

MK-2206 - Drug Profile 165

napabucasin - Drug Profile 168

nivolumab - Drug Profile 171

NUC-1031 - Drug Profile 178

OCVC-01 - Drug Profile 180

OXY-111A - Drug Profile 181

paclitaxel albumin bound - Drug Profile 183

paclitaxel albumin free - Drug Profile 187

PAN-622 - Drug Profile 189

pembrolizumab - Drug Profile 190

PLX-8394 - Drug Profile 199

ponatinib hydrochloride - Drug Profile 201

porfimer sodium - Drug Profile 204

refametinib - Drug Profile 206

regorafenib - Drug Profile 209

resminostat - Drug Profile 213

RRX-001 - Drug Profile 218

SAR-408701 - Drug Profile 220

seribantumab - Drug Profile 221

silmitasertib - Drug Profile 224

SPI-1620 - Drug Profile 226

sunitinib malate - Drug Profile 228

trametinib dimethyl sulfoxide - Drug Profile 232

Vaccine for Metastatic Cholangiocarcinoma - Drug Profile 235

varlitinib - Drug Profile 236

Vas-01 - Drug Profile 239

vemurafenib - Drug Profile 241

Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 245

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 387

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 389

Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 390

Featured News & Press Releases 390

Appendix 398

Methodology 398

Coverage 398

Secondary Research 398

Primary Research 398

Expert Panel Validation 398

Contact Us 398

Disclaimer 399

Read More http://www.idatainsights.com/reports-landing-page.php?id=179116/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.